Graham Cox to join eZono as CEO

JENA, Germany, 6th May 2013 - eZono AG (“eZono”), a private corporation that designs, develops and distributes state of the art tablet ultrasound systems, today announced a leadership transition that will accelerate the company’s growth. eZono’s supervisory board has appointed Graham D. Cox as the company’s Chief Executive Officer effective 1st June 2013. Mr. Cox will succeed Allan R. Dunbar, co-founder and acting CEO of eZono, who remains with the company as Chief Commercial Officer.

“We are very excited that Graham is bringing his skill, experience and remarkable track record to eZono. I firmly believe that, together with Allan and the team, he will enable the company to realise its enormous potential,” said Hugo Harrod of MVM Life Science Partners, lead investor in eZono.

“Graham is the best candidate for eZono CEO in the world. I’m really happy he will join so we can bring the benefits of our innovative solutions, such as eZono’s groundbreaking needle guidance, to more clinicians and patients across the globe,” commented Allan Dunbar.

“eZono has an impressive and unique team with a proven ability to innovate in the field of portable ultrasound. I am very excited to join the company and take these innovations to market worldwide,” added Graham Cox.

Mr. Cox is an ultrasound industry veteran with more than 35 years of experience in the field. He joins eZono from SonoSite, a recognised leader in point-of-care ultrasound. At Sonosite, he served as Senior Vice President, Worldwide Sales & Distribution. During his 13 year tenure, annual revenues grew from zero to over $250 Million. Prior to joining SonoSite, Mr. Cox also held senior positions running sales and distribution for ATL Ultrasound (now Philips Medical Systems) and Acuson (now Siemens AG). Mr. Cox received an electronic engineer education and holds an Executive MBA (Hon) from the International Management Centers Association.

eZono AG

eZono AG
Portable ultrasound



DownloadPress Release

Latest News

MVM invests in MDxHealth SA

MVM closed a growth investment in MDxHealth SA, a company that markets tests that optimize the care of patients with prostate cancer.

MVM leads investment round in SkyCell

MVM led the growth investment round in SkyCell, a company that has developed patented temperature-control technology to transport vaccines and biotechnology drugs.

Valneva and Pfizer announce collaboration on Lyme Disease vaccine, VLA-15

Valneva and Pfizer announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.

MVM Partners LLP Closes Fund V

MVM Partners announces the closing of a $325 million healthcare fund, MVM V.

HLS Therapeutics announces Health Canada approval for Vascepa® to reduce the risk of cardiovascular events

HLS Therapeutics announces that Health Canada has approved the use of Vascepa® to reduce the risk of cardiovascular events in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor.

Biotheranostics launches Not Another Minute campaign for its Breast Cancer Index® test

Biotheranostics announces the launch of its Not Another minute campaign, revealing how Breast Cancer Index is changing the game for early-stage, hormone receptor-positive breast cancer patients.